Market Insights
Follicular lymphoma is a type of cancer that starts in your white blood cells and progresses to create new and more severe symptoms, such as cancer spreading to other body parts. It is slow-growing cancer, and many people with this type have an excellent quality of life and live for an extended period. When it’s diagnosed, the symptoms are usually moderate or non-existent. Follicular lymphoma starts impacting a person’s mental state before it impacts physical well-being.
Around 2.7 of every 100,000 people are diagnosed with this cancer annually. It is the most prevalent type of indolent lymphoma or lymphoma that grows slowly. Follicular lymphoma disease is commonly found in people 65 and older. The male population is more prone to this disease as compared to females. According to a recent study, people with this disease and other slow-growing lymphomas usually suffer from anxiety.
Report Key Takeaways
Recommended Medications/Treatments for Follicular Lymphoma
Radiation therapy may be used to treat follicular lymphoma in its early stages. Radiation kills cancer cells by emitting high-energy beams. People in stages 1 or 2 of this disease are frequently given therapy. In some cases, radiation therapy is enough to cure cancer.
Chemotherapy can be used alone or in combination with other therapies by healthcare providers. Chemotherapy is a treatment that uses medications to eliminate cancer cells in the body. It’s usually used in a proportion of the other treatments, such as in conjunction with other treatments, radiation therapy, or monoclonal antibodies.
Follicular lymphoma is occasionally treated with a stem cell transplant, especially if the malignancy returns. In these surgeries, healthy stem cells are infused into the patient’s body to replace them with damaged bone marrow. However, it’s usually just possible for folks in generally good health.
Monoclonal antibodies are commonly used drugs for this cancer, allowing immune cells to fight cancer. Rituximab is one of the widely used monoclonal antibodies for treating follicular lymphoma.
Recent Developments Related to Follicular Lymphoma
Roche has received an official grant from the European Commission for Lunsumio with a conditional marketing authorization. The medication is developed explicitly to effectively treat adult patients with follicular lymphoma. The antibody is for patients who had previously undergone at least two systemic treatments. According to the company, the antibody is a new immunotherapy type that is a chemotherapy-free and off-the-shelf treatment alternative that improves patient outcomes.
The FDA has approved tisagenlecleucel, also known as Kymriah, to treat adult patients with follicular lymphoma (FL) who have previously failed two or more systemic therapy rounds. As a result, adult patients who are detected with follicular lymphoma cancer can now take the benefit of tisagenlecleucel. It will be the therapy’s third indication since the FDA first approved it as antigen receptor T-cell therapy.
Major Players Working on Follicular Lymphoma
Leading companies such as ADC Therapeutics, Syndax Pharmaceuticals, Xynomic Pharmaceuticals, Incyte Corporation, Janssen, Merck & Co, Dr. Reddy’s Laboratories, Shanghai Yingli Pharmaceutical, Genentech, and Novartis are working closely to develop practical solutions for the treatment of follicular lymphoma.
Key Reasons to Purchase This Report
- The pipeline insight covers a detailed analysis of different therapeutic drugs in various development phases and the result analysis of various clinical trials.
- A broader outlook of significant events took place on the global platform in the form of substantial acquisitions, expansion, collaborations, and licensing, coupled with an overview of modern drugs.
